

Francisca Gonzalez-Rubio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/449567/publications.pdf>

Version: 2024-02-01

43
papers

1,291
citations

430442

18
h-index

360668

35
g-index

54
all docs

54
docs citations

54
times ranked

2213
citing authors

#	ARTICLE	IF	CITATIONS
1	Multimorbidity Patterns in Primary Care: Interactions among Chronic Diseases Using Factor Analysis. PLoS ONE, 2012, 7, e32190.	1.1	203
2	Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well?. British Journal of General Practice, 2012, 62, e821-e826.	0.7	163
3	Baseline Chronic Comorbidity and Mortality in Laboratory-Confirmed COVID-19 Cases: Results from the PRECOVID Study in Spain. International Journal of Environmental Research and Public Health, 2020, 17, 5171.	1.2	83
4	Adherence to chronic medication in older populations: application of a common protocol among three European cohorts. Patient Preference and Adherence, 2018, Volume 12, 1975-1987.	0.8	68
5	Association between physical activity, multimorbidity, self-rated health and functional limitation in the Spanish population. BMC Public Health, 2014, 14, 1170.	1.2	64
6	Relationship of colonoscopy-detected serrated polyps with synchronous advanced neoplasia in average-risk individuals. Gastrointestinal Endoscopy, 2013, 78, 333-341.e1.	0.5	62
7	Cohort Profile: The Epidemiology of Chronic Diseases and Multimorbidity. The EpiChron Cohort Study. International Journal of Epidemiology, 2018, 47, 382-384f.	0.9	61
8	Polypharmacy Patterns: Unravelling Systematic Associations between Prescribed Medications. PLoS ONE, 2013, 8, e84967.	1.1	54
9	Correlation between adenoma detection rate in colonoscopy and fecal immunochemical testing-based colorectal cancer screening programs. United European Gastroenterology Journal, 2017, 5, 255-260.	1.6	46
10	Patterns of multimorbidity and polypharmacy in young and adult population: Systematic associations among chronic diseases and drugs using factor analysis. PLoS ONE, 2019, 14, e0210701.	1.1	41
11	Evolution of polypharmacy in a spanish population (2005-2015): A database study. Pharmacoepidemiology and Drug Safety, 2020, 29, 433-443.	0.9	38
12	Multimorbidity Patterns in the General Population: Results from the EpiChron Cohort Study. International Journal of Environmental Research and Public Health, 2020, 17, 4242.	1.2	37
13	Underreporting of recognized adverse drug reactions by primary care physicians: an exploratory study. Pharmacoepidemiology and Drug Safety, 2011, 20, 1287-1294.	0.9	36
14	Effectiveness of an intervention for improving drug prescription in primary care patients with multimorbidity and polypharmacy: study protocol of a cluster randomized clinical trial (Multi-PAP) Tj ETQq0 0 0 rgBT.# Overlock 10 Tf 50		
15	Chronic diseases associated with increased likelihood of hospitalization and mortality in 68,913 COVID-19 confirmed cases in Spain: A population-based cohort study. PLoS ONE, 2021, 16, e0259822.	1.1	31
16	Global health care use by patients with type-2 diabetes: Does the type of comorbidity matter?. European Journal of Internal Medicine, 2015, 26, 203-210.	1.0	30
17	Risk of Advanced Proximal Neoplasms According to Distal Colorectal Findings: Comparison of Sigmoidoscopy-Based Strategies. Journal of the National Cancer Institute, 2013, 105, 878-886.	3.0	25
18	Treatment Patterns of Diabetes in Italy: A Population-Based Study. Frontiers in Pharmacology, 2019, 10, 870.	1.6	23

#	ARTICLE	IF	CITATIONS
19	Multimorbidity clusters in patients with chronic obstructive airway diseases in the EpiChron Cohort. <i>Scientific Reports</i> , 2021, 11, 4784.	1.6	17
20	Do Centenarians Die Healthier than Younger Elders? A Comparative Epidemiological Study in Spain. <i>Journal of Clinical Medicine</i> , 2020, 9, 1563.	1.0	15
21	Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 615-624.	0.9	14
22	Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1708-1716.e4.	2.4	13
23	Adherence to treatment of hypertension, hypercholesterolaemia and diabetes in an elderly population of a Spanish cohort. <i>Medicina Clínica (English Edition)</i> , 2019, 153, 1-5.	0.1	12
24	Drug Prescription Profiles in Patients with Polypharmacy in Spain: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 4754.	1.2	12
25	Adherencia al tratamiento de hipertensi3n arterial, hipercolesterolemia y diabetes en poblaci3n anciana de una cohorte espa3ola. <i>Medicina Cl3nica</i> , 2019, 153, 1-5.	0.3	11
26	Identifying multimorbidity profiles associated with COVID-19 severity in chronic patients using network analysis in the PRECOVID Study. <i>Scientific Reports</i> , 2022, 12, 2831.	1.6	10
27	Health of Spanish centenarians: a cross-sectional study based on electronic health records. <i>BMC Geriatrics</i> , 2019, 19, 226.	1.1	9
28	Training primary care professionals in multimorbidity management: Educational assessment of the eMULTIPAP course. <i>Mechanisms of Ageing and Development</i> , 2020, 192, 111354.	2.2	8
29	Multimorbidity and weight loss in obese primary care patients: longitudinal study based on electronic healthcare records. <i>BMJ Open</i> , 2015, 5, e006227-e006227.	0.8	7
30	Initial Therapy, Regimen Change, and Persistence in a Spanish Cohort of Newly Treated Type 2 Diabetes Patients: A Retrospective, Observational Study Using Real-World Data. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3742.	1.2	7
31	Baseline Drug Treatments as Indicators of Increased Risk of COVID-19 Mortality in Spain and Italy. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11786.	1.2	6
32	Changes in Multimorbidity and Polypharmacy Patterns in Young and Adult Population over a 4-Year Period: A 2011-2015 Comparison Using Real-World Data. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 4422.	1.2	5
33	How to Improve Healthcare for Patients with Multimorbidity and Polypharmacy in Primary Care: A Pragmatic Cluster-Randomized Clinical Trial of the MULTIPAP Intervention. <i>Journal of Personalized Medicine</i> , 2022, 12, 752.	1.1	5
34	Shock anafil3ctico por omeprazol. <i>Gastroenterolog3a Y Hepatolog3a</i> , 2017, 40, 20-21.	0.2	4
35	Influenza Vaccination: An Ally to Mitigate Influenza-associated Risks During the Coronavirus Disease 2019 (COVID-19) Pandemic. <i>Clinical Infectious Diseases</i> , 2021, 72, 2249-2250.	2.9	4
36	Multimorbidity Profiles and Infection Severity in COVID-19 Population Using Network Analysis in the Andalusian Health Population Database. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3808.	1.2	4

#	ARTICLE	IF	CITATIONS
37	Melanosis coli asociada a diacereÃna. GastroenterologÃa Y HepatologÃa, 2017, 40, 93-95.	0.2	3
38	Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany. Pharmacoepidemiology and Drug Safety, 2018, 27, 953-961.	0.9	2
39	Effectiveness of the MULTIPAP Plus intervention in youngest-old patients with multimorbidity and polypharmacy aimed at improving prescribing practices in primary care: study protocol of a cluster randomized trial. Trials, 2022, 23, .	0.7	2
40	Hipovitaminosis D: buscando la evidencia. Endocrinologia, Diabetes Y NutriciÃn, 2017, 64, 512-513.	0.1	1
41	Urgencia en AtenciÃn Primaria: cuadros distÃnicos secundarios a la toma de neurolÃpticos. Semergen, 2009, 35, 357-358.	0.2	0
42	Anaphylactic shock due to omeprazole. GastroenterologÃa Y HepatologÃa (English Edition), 2017, 40, 20-21.	0.0	0
43	Analytical errors due to biotin interference. Medicina ClÃnica, 2021, 157, 95-96.	0.3	0